向不耐药的酸酶通过抑制多种瘤性激酶来克服特拉斯图祖马布耐药性
Lu Wang1, Yusheng Lin2, Zhimeng Yao3
1Department of General Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China; State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, and Institute of Precision Cancer Medicine and Pathology, School of Medicine, Jinan University, Guangzhou, China; Zhuhai Institute of Jinan University, Zhuhai, China.
研究人员确定了蛋白质氨酸酸酶受体O型 (PTPRO) 是克服HER2+癌症中特鲁苏马布耐药性的关键. 新型纳米粒子传递saRNA有效地调节了PTPRO,通过向关键瘤性途径恢复药物敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 特拉斯图祖马布耐药性是治疗HER2阳性癌症的一个主要挑战.
- 蛋白氨酸酸酶 (PTPs) 在这种耐药性中的作用尚未完全理解.
研究的目的:
- 确定关键的 PTP 涉及到对 trastuzumab 的耐药性.
- 制定一种新的策略来抵消这种阻力.
主要方法:
- 选公共数据集以确定与特鲁祖马布反应相关的PTP候选者.
- 利用氨酸激酶阵列,发现受PTPRO影响的激酶.
- 通过纳米颗粒传递的小激活RNA (saRNA) 进行了测试,以调节PTPRO并减轻临床前模型中的耐药性.
主要成果:
- 确定了PTPRO作为一个影响trastuzumab反应和生存的关键PTP.
- PTPRO去化ERBB3和其他铁氨酸激酶,抑制抗药性途径.
- 通过使用装载saRNA的纳米粒子成功升级PTPRO,通过抑制ERBB3,ERBB2和SRC信号来抵消电阻.
结论:
- PTPRO是克服逆苏祖马布耐药性的一个关键目标.
- 抗体结合的saRNA提供了一种创新的方法,用于准以前"无法治疗"的PTP.
更多相关视频
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
